PATIENT PREFERENCES FOR TREATMENT SELECTION IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC): A SYSTEMATIC LITERATURE REVIEW (SLR)

Author(s)

Takahiro Osawa, MD1, Raf De Moor, MSc2, Masaki Yoshida, PhD2, Dee Lin, PharmD3, David Bin-Chia Wu, PhD4, Samantha Craigie, MSc5, Imtiaz Samjoo, BSc, MSc, PhD6, Hiroshi Kitamura, MD7;
1Niigata University, Niigata, Japan, 2Johnson & Johnson, Tokyo, Japan, 3Johnson & Johnson, Titusville, NJ, USA, 4Janssen Asia Pacific, Singapore, Singapore, 5EVERSANA, Burlington, ON, Canada, 6EVERSANA, Vice President, Evidence Synthesis, Burlington, ON, Canada, 7University of Toyama, Toyama city, Japan
OBJECTIVES: To conduct an SLR on patient preferences for treatment decision-making and attributing factors relating to these preferences in patients with NMIBC in Japan and globally.
METHODS: Embase, Ovid MEDLINE®, Cochrane CENTRAL, and Cochrane Database of Systematic Reviews were searched from 01 January 2014 through 19 August 2025 for relevant English- or Japanese-language studies. Supplementary searches of the Japanese databases J-Stage (English and Japanese language) and Ichushi Web (Japanese language) were conducted. Bibliographies of included studies were also scanned. Study selection was performed independently by two reviewers. Study characteristics, patient characteristics, and outcomes of interest were extracted.
RESULTS: Twelve studies were identified. Studies were primarily based in North America and Europe. Methods of eliciting preferences included choice experiments (n = 4), standard gamble (n = 2), rank ordering (n = 1), focus groups/interviews (n = 3) and methodology not reported (n = 2). Patients preferred bladder sparing treatments over radical cystectomy (RC) and felt nonsurgical options ought to be available. Delaying RC as long as possible and preserving one’s bladder were of high importance, with fears for reduced quality of life and sexual function among reasons provided. Alternatives to TURBT were also prioritized, with patients wishing to avoid pain, catheters, and anesthesia. Patients preferred less invasive, less frequent, and less time-consuming modes of therapy administration, these factors were secondary to disease progression and bladder preservation for decision-making. Similarly, while side effects mattered to patients, they would accept higher risks of side effects to delay progression, delay RC, and extend life. Patients prioritized high sensitivity/accuracy of long-term surveillance methods for recurrence.
CONCLUSIONS: Reduced risk of disease progression and bladder preservation emerged as top treatment attributes for patient decision-making in NMIBC. No insights into Japanese patients’ preferences for treatments were identified. Further evidence is needed to address the specific needs of Japanese patients with NMIBC.

Conference/Value in Health Info

2026-05, ISPOR 2026, Philadelphia, PA, USA

Value in Health, Volume 29, Issue S6

Code

PCR15

Topic

Patient-Centered Research

Topic Subcategory

Patient Behavior and Incentives

Disease

SDC: Oncology, SDC: Urinary/Kidney Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×